Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the above-referenced application.

1 – 6 (canceled)

7. (previously presented) An antimalarial composition comprising an inhibitor of fatty acid synthesis of the malarial parasite for treating malaria in an amount effective for the treatment of malaria.

8. (previously presented) An antimalarial composition comprising an inhibitor of fatty acid synthesis in combination with one or more known antimalarials and a pharmaceutically acceptable adjuvant, diluent, or carrier.

9. (currently amended) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis used is a hydroxydiphenyl ether of general formula 2 given below wherein the two phenyl rings (I & II) are joined by an oxygen (X=O) atom and either R_1 or R_2 represent a hydroxy (OH) group and the other being a hydrogen atom, respectively, or both being hydroxy groups and other positions (R_3 to R_{10}) of the phenyl rings I and II being selected from the group consisting of chlorine, bromine or iodine atoms or hydroxy, aldehyde or keto groups or hydrogen atoms or ester groups ~~and~~.



Formula 2

10. (previously presented) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis is triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol] having formula 1 given below:



Formula 1

11. (previously presented) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether having formula 3 given below.



Formula 3

12. (previously presented) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl thioether having formula 5 given below:



Formula 5

13. (previously presented) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis a hydroxydiphenyl methane analog having formula 7 given below:



Formulas 7

14. (canceled)

15. (previously presented) An antimalarial composition as claimed in claim 7 for treating a malarial condition wherein the amount of the fatty acid synthesis inhibitor used is in the dosage range of 0.03 mg/kg to 100 mg/kg for a human or an animal subject for treating a malarial condition.

16. (previously presented) An antimalarial composition as claimed in claim 7 wherein the inhibitor of fatty acid synthesis used is cerulenin.

19. (withdrawn) An antimalarial drug target comprising a component of a fatty acid synthesis pathway in a malarial parasite, wherein the component is selected from the group consisting of (ß-hydroxydecanoyl-ACP dehydrase, ß-ketoacyl-ACP synthase I, malonyl-CoA:ACP transacylase, ß-ketoacyl-ACP synthase II, ß-ketoacyl-ACP reductase, ß-ketoacyl-ACP-synthase III, enoyl-ACP reductase, or ß-hydroxyacyl-ACP dehydrase, and wherein the malarial parasite used is *P. falciparum*.

20. (withdrawn) An antimalarial drug target comprising a component of a fatty acid synthesis pathway in a malarial parasite, wherein the component is selected from the group consisting of (ß-hydroxydecanoyl-ACP dehydrase, ß-ketoacyl-ACP synthase I, malonyl-CoA:ACP

transacylase, ß-ketoacyl-ACP synthase II, ß-ketoacyl-ACP reductase, ß-ketoacyl-ACP-synthase III, enoyl-ACP reductase, or ß-hydroxyacyl-ACP dehydrase.

21-35. (canceled)

36. (currently amended) ~~The~~ An antimalarial composition comprising the compound of formula 9, wherein X is selected from the group consisting of O, S, and CH_2, wherein at least one of the positions R_9 or R_4 or R_7 or R_6 is an aldehyde group or a ketone group having at least 5 C atoms, wherein R_1 or R_2 is a hydroxyl (OH) group with the other being a hydrogen atom, and wherein at least one of R_1 to R_{10} is a halogen atom.



Formula 9

37. (currently amended) ~~The~~ An antimalarial composition comprising the compound of formula 9, wherein X is selected from the group consisting of O, S, and CH_2, wherein at least one of the positions R_9 or R_4 or R_7 or R_6 is an aldehyde group or a ketone group having at least 5 C atoms, wherein R_1 and R_2 are hydroxyl (OH) groups, and wherein at least one of R_1 to R_{10} is a halogen atom.



Formula 9

38. (currently amended) [[A]] <u>An antimalarial composition comprising a</u> compound selected from the group consisting of formulas 10 – <u>15</u> ~~11~~ below, wherein R is selected from the group consisting of: H and ketones having at least 5 C atoms:



Formula 10



Formula 11



Formula 12



Formula 13



Formula 14



Formula 15

39. (currently amended) The antimalarial composition ~~compound~~ of claim 38, wherein R is H.

40. (currently amended) [[A]] An antimalarial composition comprising a compound having formula 16:



Formula 16

41. (currently amended) [[A]] An antimalarial composition comprising a compound of general formula 2 given below wherein the two phenyl rings (I & II) are joined by a sulfur atom (X = S) and either R_1 or R_2 is a hydroxyl (OH) group with the other being a hydrogen atom, respectively, or both being hydroxyl groups, and substituents at other positions (R_3 to R_{10}) of the phenyl rings I and II being selected from the group consisting of hydrogen, chlorine, bromine or iodine atoms or hydroxyl, aldehyde, ester, or keto groups.



Formula 2

42. (currently amended) [[A]] An antimalarial composition comprising a compound of general formula 2 given below wherein the two phenyl rings (I & II) are joined by a CH_2 group and either R_1 or R_2 is a hydroxyl (OH) group with the

other being a hydrogen atom, respectively, or both being hydroxyl groups, and substituents at other positions (R_3 to R_{10}) of the phenyl rings I and II being selected from the group consisting of hydrogen, chlorine, bromine or iodine atoms or hydroxyl, aldehyde, ester, or keto groups.



Formula 2

43. (previously presented) The antimalarial composition of claim 9, wherein the malarial parasite is a drug resistant malarial parasite.

44. (currently amended) The antimalarial composition of claim 8, wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether.

45. (currently amended) The antimalarial composition of claim 8, wherein the inhibitor of fatty acid synthesis is triclosan.

46. (currently amended) The antimalarial composition of claim 8, wherein the inhibitor of fatty acid synthesis is cerulenin.

47. (currently amended) The antimalarial composition of claim 8, wherein the known antimalarial is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, and artemether.

48. (currently amended) The antimalarial composition of claim 8, wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether and the known antimalarial is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, and artemether.

49. (currently amended) The antimalarial composition of claim 8, wherein the inhibitor of fatty acid synthesis is selected from the group consisting of triclosan and cerulenin and the known antimalarial is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, and artemether.

50. (currently amended) [[A]] An antimalarial composition comprising triclosan and cerulenin.